Intraperitoneal Galanthamine treatment reduced deposited SAA in FMF-KI mice compared with PBS-treated controls. In male Wistar rats, Galanthamine pretreatment significantly increased Ki67+IR in both AIE and CON groups relative to vehicle-treated rats. In LPS-exposed male Kunming mice treated with Galanthamine, escape latency during training was significantly decreased in the LPS + galantamine group compared with the LPS group. In α7nAChR deficient FMF-KI mice, Galanthamine treatment resulted in significantly smaller spleens compared with PBS-treated controls. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced SAA deposition in FMF-KI mice
Animal study · FMF-KI mice; treated animals (n = 2) compared with controls (n = 3) [1]
FMF-KI mice received intraperitoneal Galanthamine at an escalated dose of 4–12 mg/kg. Treated animals showed ~ 50% reduction in deposited SAA compared with PBS-treated controls.
Conditions shared by the study groups
- Route
- intraperitoneally (i.p.)
- Treatment course
- twice daily for 8 weeks
- Vehicle
- PBS
- Galanthamine 4–12 mg/kg
- Model: FMF-KI mice; treated animals (n = 2) compared with controls (n = 3)
Methods and source locations
Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animal experiments (S7, S8); Results > Galantamine lowers markers of chronic inflammation (S74, S76, S80, S81)
SAA deposition; Band density was quantified with ImageJ and normalized by actin: SAA deposition; Band density was quantified with ImageJ and normalized by actin; comparator: PBS-treated (Ct) FMF-KI mice — Materials and methods > Animal experiments (S8); Results > Galantamine lowers markers of chronic inflammation (S74, S76, S80, S81)
Galanthamine 4–12 mg/kg · Materials and methods > Animal experiments (S8); Results > Galantamine lowers markers of chronic inflammation (S74, S76)
Ki67+IR Following Pretreatment in Male Wistar Rats
Animal study · male Wistar rats [2]
Male Wistar rats received Galanthamine by intraperitoneal injection before ethanol or water gavage. Pretreatment significantly increased Ki67+IR in both AIE and CON groups relative to vehicle-treated rats.
Conditions shared by the study groups
- Route
- intraperitoneal injection (i.p.)
- Treatment course
- 30 min prior to either ethanol or water gavage on every gavage treatment day of the AIE paradigm; 16 doses across 30 days; Treatment ended on P54; until P70
- Vehicle
- saline (vehicle)
- Galanthamine 4 mg/kg
- Model: male Wistar rats
Methods and source locations
Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S10, S12, S13); Materials and methods > Galantamine treatment and euthanasia (S29, S30); Results > Study 1 (prevention): mechanisms of AIE-reduced adult neurogenesis and galantamine prevention (S111, S127); Table 6 (T6.h1, T6.r1)
Ki67+IR: Ki67+IR; comparator: CON-Veh — Results > Study 1 (prevention): mechanisms of AIE-reduced adult neurogenesis and galantamine prevention (S111, S127); Table 6 (T6.h1, T6.r1)
Galanthamine 4 mg/kg · Materials and methods > Animals (S12, S13); Materials and methods > Galantamine treatment and euthanasia (S29, S30); Results > Study 1 (prevention): mechanisms of AIE-reduced adult neurogenesis and galantamine prevention (S111, S127); Table 6 (T6.h1, T6.r1)
Escape Latency in LPS-Exposed Mice
Animal study · Male Kunming mice; LPS-exposed mice; 10 mice per group [3]
LPS-exposed male Kunming mice received Galanthamine by intraperitoneal injection beginning before LPS injection. Escape latency during training was significantly decreased in the LPS + galantamine group compared with the LPS group.
Conditions shared by the study groups
- Route
- ip injection
- Treatment course
- for 14 days starting 1 day before the LPS injection
- Galanthamine 4 mg/kg
- Model: Male Kunming mice; LPS-exposed mice; 10 mice per group
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine
Evidence for Galanthamine as the hydrobromide form reported in the paper, not the free base/neutral form supplied as A12483; no salt equivalence, dose conversion or lot validation.
Methods > Animals (S1); Methods > Experimental protocol (S5, S6, S7, S9, S11); Results > Galantamine improves cognition in LPS-exposed mice (S81, S82)
escape latency during training days 2–4: escape latency during training days 2–4; comparator: the LPS group—vehicle treatment and ICV injection of LPS — Results > Galantamine improves cognition in LPS-exposed mice (S82)
Galanthamine 4 mg/kg · Methods > Experimental protocol (S7); Results > Galantamine improves cognition in LPS-exposed mice (S82)
Spleen Size in α7nAChR Deficient FMF-KI Mice
Animal study · α7nAChR deficient FMF-KI mice; treated n = 5; control n = 4 [1]
α7nAChR deficient FMF-KI mice received Galanthamine intraperitoneally. Treated mice had significantly smaller spleens compared with PBS-treated controls.
Conditions shared by the study groups
- Route
- intraperitoneally (i.p.)
- Treatment course
- 4–6 weeks of treatment with galantamine (escalated to 12 mg/kg twice daily) starting at age ~ 4–5 weeks
- Vehicle
- PBS
- Galanthamine escalated to 12 mg/kg
- Model: α7nAChR deficient FMF-KI mice; treated n = 5; control n = 4
Methods and source locations
Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animal experiments (S7, S8); Results > Galantamine controls splenomegaly in vagotomized and α7nAChR knockout (α7-KO) FMF-KI mice (S93, S99)
Spleen sizes (mg): Spleen sizes (mg); comparator: PBS-treated controls — Results > Galantamine controls splenomegaly in vagotomized and α7nAChR knockout (α7-KO) FMF-KI mice (S93, S99)
Galanthamine escalated to 12 mg/kg · Materials and methods > Animal experiments (S8); Results > Galantamine controls splenomegaly in vagotomized and α7nAChR knockout (α7-KO) FMF-KI mice (S93, S99)